ACell Announces New Research Investigating its Hernia Devices in Regenerative Medicine
Pre-Clinical Model Demonstrates Mechanical Strength and Superior Tissue Remodeling Properties of Gentrix® Surgical Matrix Devices
COLUMBIA, Md., Oct. 4, 2018 /PRNewswire/ -- ACell, Inc. today announced the publication ahead of print of the article entitled "Comparison of in vivo remodeling of urinary bladder matrix and acellular dermal matrix in an ovine model" in the journal Regenerative Medicine.
The peer-reviewed article compared the mechanical strength and remodeling response of Gentrix Surgical Matrix Plus, a biologically-derived mesh manufactured using ACell's proprietary MatriStem UBM™ technology, and a porcine Acellular Dermal Matrix (ADM) when implanted to repair a fascial tissue defect in sheep.
As presented in the data, the devices had distinctly different responses post-implantation. Gentrix Surgical Matrix was completely resorbed and replaced by site-appropriate tissue that demonstrated increasing mechanical strength over the 3 month remodeling process, with levels similar to or above that of native fascia throughout the observed period. In contrast, the ADM persisted at the repair site during the same time frame, showed limited host tissue growth into the device, demonstrated a persistent inflammatory response, and showed a decreasing trend in mechanical strength.
"Historically, the clinical community has generally considered that all biologically-derived surgical grafts perform the same," said Thomas W. Gilbert, Chief Science Officer. "This research highlights that there are indeed substantial differences in the host response and resulting mechanical behavior between various biologically-derived materials over time, and that device remodeling characteristics should be as equally weighted as pre-implantation strength when evaluating different surgical graft materials."
"This paper contributes to the growing body of research supporting the use of Gentrix Surgical Matrix in complex hernia repairs," said Patrick McBrayer, President and CEO. "Several publications this year have clearly demonstrated the strength of our devices and their ability to facilitate remodeling of biomechanically functional tissue. All of this supports our goal of offering a biologically-derived alternative that meets the needs of surgeons and patients."
To read the full article, visit www.acell.com/ovine.
About ACell, Inc.
About Gentrix Surgical Matrix
SOURCE ACell, Inc.